Trevi Therapeutics, Inc.
12.61USD
-0.3300 (-2.55%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TRVI.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -21 | -15 | -10 | -14 | -14 | -11 | -12 | -14 |
| Net Income | -18 | -13 | -8 | -12 | -12 | -10 | -11 | -13 |
| EPS (Diluted) | -$0.11 | -$0.09 | -$0.06 | -$0.08 | -$0.09 | -$0.09 | -$0.11 | -$0.13 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)